Day One Biopharmaceuticals, Inc. (DAWN) shares rallied 7% in the last trading session to close at $7.95. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.3% gain over the past four weeks.The price rise can be attributed to growing investor optimism related to the strong uptake of the company’s lead marketed drug, Ojemda, a type II RAF inhibitor, which is approved for treating patients aged six months and old ...